The Insivio Drug Discovery Platform brings enterprise-grade computational drug discovery to researchers, academics, and emerging biotech teams — at a cost structure that makes it viable for the first time.
Computational drug discovery at the enterprise level is scientifically mature. The databases exist. The methods are validated. The literature is deep. What does not exist — for most of the world’s researchers — is practical access to these capabilities in a unified, affordable, automated form.
Traditional computational platforms are priced exclusively for large pharmaceutical companies. Researchers at academic institutions and early-stage biotechs are locked out of the same capabilities by cost alone.
Free tools require extensive expertise to set up, integrate, and maintain. For most scientists, the overhead of building their own pipeline is a barrier that prevents them from doing the science at all.
Researchers in ASEAN, Africa, and Latin America face the widest gap — strong scientific talent, limited infrastructure access. Insivio was built to close that gap.
The Insivio platform orchestrates a full drug discovery workflow — from target identification through ADMET profiling and IP assessment — in a single, automated process.
Structure-based target identification, virtual screening against validated compound libraries, lead optimization, and ADMET profiling — delivered as a research-grade report with full database citations.
Integrates automatically with leading public scientific databases so researchers receive structured, cited outputs rather than raw search results.
Target validation, siRNA sequence design, off-target analysis, and delivery strategy — for researchers pursuing gene-silencing approaches to hard-to-drug biology.
Built on the same RNAi science that drives our own in-house therapeutics programs — validated methodology, not a theoretical workflow.
Most AI tools in research are point solutions — one for literature, one for docking, one for ADMET. Connecting them requires expertise, time, and often a specialist team. The Insivio platform uses agentic AI: multiple specialized modules that coordinate in sequence, passing findings forward, making analytical decisions, and synthesizing results into a coherent scientific document.
You define the target. The platform runs the science.
ChEMBL, PubMed, and Open Targets queried automatically — no manual search required.
Freedom-to-operate analysis runs as part of every pipeline — not as a separate step.
Fully cited preclinical report generated automatically — ready for grant applications or internal review.
Every pipeline run generates a structured preclinical report containing the following — fully cited and exportable.
All platform outputs are for research use only. AI predictions require experimental validation before any regulatory, clinical, or commercial application.
PhD researchers and postdocs running target validation or early hit discovery without institutional access to commercial platforms. Real computational output, not just a literature summary.
Early-stage biotechs and spinouts in ASEAN, Africa, Latin America, and other markets where enterprise software is financially out of reach. The full pipeline without an enterprise contract.
Medicinal chemists, computational biologists, and drug discovery professionals working independently or across multiple programs. Your workflow, your reports, your project history in one place.
Universities and research institutes running drug discovery programs at department or cohort scale. We offer custom institutional access arrangements and co-development partnerships.
Insivio works with universities, research institutes, and accelerator programs to provide platform access at scale. If your institution runs drug discovery programs and needs a computational infrastructure solution — for a department, a cohort, or a full research initiative — we welcome conversations about custom access arrangements and co-development partnerships.
Enquire About Institutional Access →The platform is currently in development, powered by the same AI infrastructure that drives our in-house therapeutics pipeline. Early access is available to select research partners.